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Summary Alterations in the p53 gene were analysed in 39 patients with locally advanced breast cancers
(LABCs) (stage III-IV) with inflammatory signs in most cases (UICC stage T4d = 32 patients) by molecular
and immunohistochemical (IHC) approaches. All patients were included in the same therapy protocol. Using
polymerase chain reaction (PCR) and a single-strand conformational polymorphism migration technique
(SSCP), the presence of mutations in exons 2-11, covering the entire coding sequence of the p53 gene, was
evaluated. Using the mouse specific anti-human p53 monoclonal antibody (PAb 1801), we also looked for
overexpression of the p53 protein in tissue sections. In 16 cases shifted bands were reproducibly identified by
PCR-SSCP, and all but one (localised to exon 10) were in exons 5-8, the usual mutational hotspots. Fifteen of
these 16 samples were sequenced and 14 of the suspected mutations (36%) were confirmed. Most of them (12)
were single nucleotide substitutions, and transitions were more frequent (eight cases) than transversions (four
cases). Fourteen of the tumour samples were positively stained with the monoclonal antibody PAb 1801, 11
with nuclear staining only, two with mixed cytoplasmic and nuclear staining and one with cytoplasmic staining
only. Staining patterns were very heterogeneous in terms of the percentage of positive cells (10-75%) and
their distribution in the tissue section (isolated foci or dispersed cells). In 11 of the 14 mutated cases a positive
immunostaining was observed. The presence of a p53 mutation was significantly associated with larger tumour
diameter (X2 = 7.490, P = 0.0062) and the presence of clinical metastases (stage IV) (X2 = 10.113, P = 0.0015).
A non-statistically significant trend of association was observed between p53 mutation, negative oestrogen
receptors and lower response rate to therapy. Our results in this group of patients and the heterogeneity of the
staining of tumour cells in tissue sections suggest that p53 mutations could be a late event in this non-familial
form of breast cancer.
Locally advanced stage III and IV breast cancers (LABCs)
have a high likelihood of distant metastasis at diagnosis or
more often at recurrence, and are associated with a poor
survival even when treated with neoadjuvant chemotherapy
(Beahrs et al., 1988). A peculiar form of LABC is represented
by inflammatory breast cancers (IBCs) (stage T4d of UICC
classification) (Beahrs et al., 1988). These represent less than
5% of breast tumours and are characterised by a high fre-
quency of metastases at diagnosis and even shorter survival
than other LABCs. These forms are characterised by clinical
inflammatory signs in the breast skin and dermal lymphatic
emboli. To date, no peculiar biological characteristics for
these cancers have been described, although oestrogen recep-
tor (ER) negativity, epidermal growth factor (EGF) receptor
positivity and c-erbB2 overexpression have been reported to
be more frequent than in other LABCs (Levine et al., 1985;
Sherry et al., 1985; Jaiyesmi et al., 1992).
The tumour-suppressor gene p53 is a phosphoprotein that
negatively regulates cell proliferation and plays a role in
differentiation and apoptosis of cells (Clarke et al., 1993;
Lane, 1993; Lowe et al., 1993). Wild-type p53 has been
shown to block the cell cycle near the GI/S phase (Diller et
al., 1990; Lane, 1992). Mutational inactivation of p53
appears to be the most common genetic abnormality in
cancers (Baker et al., 1989, 1990a; Nigro et al., 1989; Caron
de Fromentel et al., 1991; Hollstein et al., 1991), leading to
the loss of growth control. p53 mutations tend to cluster in
regions between exons 5 and 8, known to include four highly
conserved sequence blocks (Nigro et al., 1989; Caron de
Fromentel et al., 1991). In colon cancers, the p53 mutation
rate is as high as 70% (Baker et al., 1989, 1990a,b), but this
event occurs in 20-40% of breast tumours (Prosser et al.,
1990; Davidoff et al., 1991a,b; Levine et al., 1991; Mazars et
al., 1992; Moll et al., 1992). While in both types of tumours
the p53 locus is reduced to homozygosity in 70% of cases
(Baker et al., 1989; Davidoff et al., 1991a,b), colon cancers
retain the mutant allele in 90% of cases (Baker et al., 1990a).
In contrast, 40% of breast tumours preferentially retain the
wild-type allele (Davidoff et al., 1991a). Therefore,
mechanisms underlying the negative regulatory effects and
the bypass of wild-type protein function are not totally
elucidated.
A large series of studies have shown that p53 mutations in
breast cancers are associated with poor clinical parameters
and bad prognosis. Most of these studies are retrospective
and deal with tumour samples from heterogeneous patients
treated with various therapies (Prosser et al., 1990; Davidoff
et al., 1991a,b; Mazars et al., 1992).
We were mostly interested in studying the mutational pat-
tern of p53 in a homogeneous group of aggressive breast
tumours, and relating this pattern to proliferation, response
to therapy and metastasis. We studied a group of 39 patients
with stage III and IV LABC, 32 of IBC type, diagnosed,
followed and treated in the same institution, and included in
the same therapy protocol. p53 mutations were sought by
both PCR-SSCP and immunostaining using PAb 1801, since
p53 mutations are characterised by overexpression of the
protein. Mutations were determined by sequence analysis.
We finally attempted to correlate these data with the usual




Thirty-nine patients who were classified as having a locally
advanced breast cancer (stage III-IV), without prior treat-
ment, were included in the SIM 85 protocol from 1985 to
1990. All these patients had an initial surgical biopsy fol-
lowed by 4-6 courses of intensive chemotherapy (4'-epi-
adriamycin and cyclophosphamide) followed by mastectomy,
radiation therapy and 6 months' maintenance chemotherapy
using a rotational regimen.
Patients were staged according to the UICC/AJCC
classification (Beahrs et al., 1988). Tumours were classified
according to WHO (1982) pathology criteria and Scarff-
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Bloom Richardson (SBR) grading system. Two patients were
suspected of having Li-Fraumeni syndrome. ER determina-
tion was made by ELISA (Abbott).
Human tumours
Breast tumour samples were obtained from patients undergo-
ing surgery. They were immediately quick frozen in liquid
nitrogen and stored at - 80°C until the extraction of DNA.
Tumour typing was done according to the WHO histological
typing of breast cancers (1982).
DNA extraction
High molecular weight genomic DNA was extracted from
tumour tissues by conventional methods (Maniatis et al.,
1982).
Single-strand conformational polymorphism (SSCP) analysis
PCR-SSCP analysis was performed according to the method
of Orita et al. (1989) with slight modifications. The
nucleotide sequences of the primers used for exons 5-8 and
10 are listed in Table I, and the sizes of the amplified
fragments are described according to the nucleotide numbers
of the Chumakov human p53 sequence (Buchman et al.,
1988). Briefly, PCR was performed with 100 ng of DNA
(1 jIl), 4 pmol of each primer, 200 mM deoxynucleotide
triphosphate, 10 mM Tris (pH 8.8), 50 mM potassium
chloride, 1 mM magnesium chloride, 1 pCi of [_-32P]dCTP
(Amersham; specific activity 3,000 Ci mmol 1) and 0.5 U of
Taq polymerase. Thirty cycles were performed using an
automated DNA Perkin-Elmer-Cetus thermocycler (model
9600) with denaturation at 92°C, annealing at 60°C for exons
2-5 and 8-11, at 65°C for exon 7 and at 55°C for exon 6,
and extension at 72°C. One microlitre of the reaction mixture
was diluted in 20 jl of 20 mM EDTA/0.1% SDS, and 2 jl of
this dilution was mixed with 2 jIl of sequencing stop solution.
Samples were heated at 95°C for 8 min, immediately cooled
at 4'C and 1.5 jLI was loaded onto a 6% polyacrylamide
non-denaturing gel. Samples were systematically run three
times at three different conditions: twice at room
temperature, 30 W, in a gel containing either 5 or 10%
glycerol, and once at 4°C in a gel without glycerol (Spinardi
et al., 1991). Gels were dried at 80°C, autoradiography was
performed with an intensifying screen for 12 h and the pat-
tern of single-stranded DNA was analysed for shifted
bands.
DNA sequencing
DNA from regions showing band shifts upon SSCP analysis
was amplified in a separate PCR and subcloned by ligation
to (pCRTmII) vector using the TA cloning kit (Invitrogen
Corporation) according to the manufacturer's instruction.
The recombinant clones were colour selected and white
recombinants were amplified. Double-stranded DNA was
then sequenced by the dideoxy chain-termination method
using a Sequenase version 2.0 kit (US Biochemicals, USA)
and priming the reaction with forward and reverse primers of
the TA cloning kit. Sequences were analysed on a 6%
polyacrylamide gel containing 7 M urea. After drying, gels
were exposed to Kodak XAR film overnight.
Immunohistochemistry
Frozen sections (4 jim) were cut, air dried and fixed in
acetone for 10 min. p53 was detected with the mouse anti-
human p53 monoclonal antibody PAb 1801 (Novocastra,
NCL-p53-1801) following the procedure of Davidoff et al.
(199la). PAb 1801 recognises an epitope between amino acids
32 and 79 at the N-terminus of both wild-type and mutant
human p53 (Banks et al., 1986). Staining was performed by
incubation at 4°C overnight with the primary antibody, fol-
lowed by incuba-tion with a biotinylated horse antibody to
mouse immunoglobulin (Vector Laboratories). The reaction
was revealed using diaminobenzidine (DAB), and the sections
were counterstained with haematoxylin and mounted. Nor-
mal mouse serum was used as a negative control. The breast
cancer cell line MDA-MB231 served as positive control.
Results
Characterisation ofp53 abnormalities recognised by
PCR-SSCP
Using PCR-SSCP, 39 tumour samples from a highly
homogeneous series of locally advanced breast cancer
patients were screened for abnormalities of the p53 gene
(Figure 1). Mutations were recognised as shifted bands on
non-denaturing polyacrylamide gels. Shifted bands due to
conformational changes produced by mutations allow the
wild-type gene to be distinguished from the mutated form of
the gene. DNA analysis was performed on every exon of the
coding sequence (exons 2-11). In those highly evolutive
breast cancers there was no specific mutational pattern. All
except one of the 16 variant conformers were found in exons
5-8, which are recognised as classical mutational hotspot
regions (Nigro et al., 1989). Exon 5 was the most frequently
involved (five cases, 12%). Four mutations were recognised
on exon 7, three on exons 6 and 8, and one on exon 10. In
nine cases out of 16, four bands were clearly detected by
SSCP, verifying that they had retained the wild-type form.
This could be caused by the presence of tumour cells contain-
ing either the wild-type or mutated form of p53 or by the
presence of both mutated and normal alleles in the same
tumour cells. In no case could this be explained by normal
tissue, the percentage of which was negligible when observed
on tissue sections.
DNA sequence analysis ofSSCP variants
We reamplified and sequenced 15 of the 16 samples with
variant conformers (Table II). A mutation was confirmed in
14 cases (36%), one sequence being normal after repeat
experiments. In 13 of these 14 cases a functional mutation
was present, while in one case there was a nonsense mutation
(patient 32). These 14 mutated cases were composed of one
intronic insertion (patient 24), one base pair deletion (patient
39) and 12 substitutions, more frequently transitions (eight
cases) than transversions (four cases).
Immunohistochemistry
Analysis of frozen sections prepared for immunohistochemi-
stry (IHC) using the anti-human p53 monoclonal antibody
PAb 1801 found 14 positive cases (36%) (Figure 2).
Examination of the slides identified different patterns of
staining: exclusively nuclear, cytoplasmic or mixed
nucleocytoplasmic. The number of positive cells was very
variable, from 10% to 75%. The distribution of positive cells
was also variable, focal in some cases, dispersed in others
(Figure 2a and b). The remaining 25 patients were negative
after extensive examination and despite the presence of
malignant epithelium throughout the specimen. Control
experiments with normal mouse serum or phosphate-buffered
saline did not show any staining, and in all cases normal
breast epithelial and stromal cells were negative and served as
internal controls. Of the 14 mutated tumours, 11 showed
nuclear staining, associated in two cases with cytoplasmic
staining. One of these two tumours showed a mutation at
codon 138. One tumour mutated at codon 342 (exon 10)
showed only cytoplasmic positivity. Of the four negative
samples, one showed a normal sequence (patient 17), one a
nonsense mutation (patient 32), one an intronic insertion
(patient 24) and one had a missense mutation at codon 283
(patient 44). Two samples positively stained with PAb 1801
did not show any shifted band with PCR-SSCP.p53 IN LOCALLY ADVANCED BREAST CANCER 1147
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Figure 1 PCR-SSCP analysis of the p53 gene. Fifteen of the 16 band shifts recognised by PCR-SSCP are reported here. DNA
, samples of breast tumours and normal tissue were amplified using PCR primers for the considered exons. Samples with shifted
bands (*) are seen in the tumour samples from patients 1, 7, 9, 39 and 43 in exon 5; patients 21-52 in exon 6; patients 17, 24, 32
and 33 in exon 7; patients 41, 44 and 47 in exon 8; patient 10 in exon 10. N, normal control tissue; M, mutated referenced cell line
for the exon considered. BT20= exon 5, T47D = exon 6, MDA-MB231 = exon 8.
Table I Primers used for SSCP studies of exons 5-8 and 10
Name of Exon Size of
primers amplified Sequence of primers DNA fragment amplified fragment (bp)
G5 s 5 5'-TTCACTTGTGCCCTGACTTTC-3' 48 bp upstream to 23 bp 250
5 R as 5'-CTCTCCAGCCCCAGCTGCTC-3' Downstream of exon 5
6N s 6 5'-ATTCCTCACTGATTGCTCTT-3' 21 bp upstream to 35 bp 169
Seq3 as 5'-CCCCTCCTCCCAGAGACCCC-3' Downstream of exon 6
M2 s 7 5'-ACAGGTCTCCCCAAGGCGCA-3' 52bp upstream to 24bp 184
Seq2 as 5'-TGCAGGGTGGCAAGTGGCT-3' Downstream of exon 7
HinI s 8 5'-GGTAGGACCTGATTTCCTTACTGCC-3' 55bp upstream to 40bp 227
HinIlI as 5'-CCCTTGGTCTCCTCCACCGCTTCTTG-3' Downstream of exon 8
ION s 10 5'-TCCCCCTCCTCTGTTGCTGC-3' 22bp upstream to 20bp 147
lOR as 5'-GTAAGGGGCTGAGGTCACTC-3' Downstream of exon 10
s refers to forward primers and 'as' to reverse primers. All of them were situated inside introns, allowing amplification and
sequencing of the complete coding sequence of exons concerned.
Table II Characterisation of the p53 mutations and overexpression
Patient SSCP shift IHC
no. exon Intron Exon Codon Mutation Amino acid change staining
1 5 5 135 TGC+TAC Cys+Tyr N + + +
7 5 5 157 GTC-*TTC Val+Phe N + +
9 5 5 138 GCC+GTC Ala+Val N +/C +
39 5 5 176 TGC->TG- Frameshift N +
43 5 5 179 CAT+CAA His+Gln N + + +
20 6 6 194 CTT-lTTT Leu-Phe N + +
21 6 NT NT NT NT N +
52 6 6 187 GGT+TGT Gly-Cys N + +
17 7 7 None detected
24 7 6 GGT- GGGT 49 bp upstream of exon 7
32 7 7 245 GGC-*GGT Gly+Gly (silent)
33 7 7 248 CGG+CAG Arg+Gln N + + +
41 8 8 266 GGA-*GAA Gly+Glu N +/C +
44 8 8 283 CGC-+TGC Arg+Cys
47 8 8 273 CGT-*TGT Arg+Cys N ++
10 10 10 342 CGA->CCA Arg+Pro C +
IHC, immunostaining, performed with PAb 1801; N, nuclear; C, cytoplasmic staining; + = 10-20% cells,
+ + = 20-50% cells, + + + = > 50% cells stained.
Correlations ofp53 mutations with clinicopathological
parameters (Table III)
Among the 16 band shifts with PCR-SSCP, 13 had mutations
leading to mRNA and protein amino acid substitution and
were considered as mutants for the clinicopathological cor-
relation. As can be seen in Table III, 82% of this series of
patients had an inflammatory form of breast cancer, and
18% had metastasis at diagnosis. Patients with p53 muta-
tions had significantly larger tumours (X2 = 7.490;
P = 0.0062) and more metastatic forms at diagnosis
(X2 = 10.113; P = 0.0015).
All but one patient with p53 mutations had ductal cancer.
Two other patients with p53 immunostaining positivity but
without p53 SSCP abnormality had a lobular breast cancer.
Patients with p53 muations had more frequently, but without
statistical significance, SBR grade III tumours, ER-negative
tumours, and lymphatic emboli. The response rate to induc-
tion chemotherapy was higher in patients without p53 muta-1148 A. FAILLE et al.
Figure 2 Examples of immunohistochemical analysis ofp53 pro-
tein in breast cancers. Tumour tissues were frozen-sectioned, fixed
in acetone and stained with monoclonal antibody against p53
(PAb 1801). Counterstaining was performed with haematoxylin.
a, Staining of tumour tissue from patients 43 (x 65). b, Staining
of tumour tissue from patient 9 (x 325) (both patients had
shifted bands on exon 5).
Table III p53 mutations and clinical characteristics of the
patients
p53 mutations
Absent (%) Present (%) Total (%)
Patients 25 (66) 13 (34) 38
Median age (years) 45 54
Tumour size> 10cm 2 (8) 6 (46) 8 (21)*
T4d 20 (80) 11 (85) 31 (82)
Stage III 24 (96) 7 (54) 31 (82)
Stage IV 1 (4) 6 (46) 7 (18)**
Pathology
Ductal 16 (64) 12 (92) 28 (74)
Non-ductal 9 (36) 1 (8) 10 (26)
SBR grading
III 10 (40) 8 (62) 18 (47)
Oestrogen receptors
Presence/tested 8/17 (47) 1/10 (10) 9/27 (33)
Response to therapy
No response 1 (4) 4 (31) 5 (13)***
CR + PRa 24 (96) 9 (69) 33 (87)
Site of relapse
Bone 4 1
Soft tissue I I
Lung and pleura 5 1
Liver 4 1
CNS 0 3
Overall survival 21/24 (87.5) 7/11 (63.6)
at 2 years (%)
aCR, complete response; PR, partial response; statistical analysis
was performed using chi-square method. *(X2 = 7.49; P = 0.006);
**(X2= 10.11; P = 0.0015); ***(X2 = 5.36; P = 0.02).
tions but there was no difference in relapse rates. Surpris-
ingly, three CNS relapses were observed in the patients with
p53 mutation.
Discussion
Using SSCP we detected p53 shifted bands in 16 (41%) of 39
patients with locally advanced and inflammatory breast
tumours. This is a fairly high percentage for breast cancers,
in which mutations recognised by this approach are generally
lower, even if they greatly vary among studies (17-46%)
(Prosser et al., 1990; Davidoff et al., 1991a,b; Osborne et al.,
1991; Coles et al., 1992; Mazars et al., 1992; Moll et al.,
1992). These data were obtained by studying the whole
coding sequence, and SSCP was performed under various
conditions known to miss very few, if any, mutations
(Spinardi et al., 1991). As a band shift may be associated
with nonsense mutation or silent polymorphism (De la Calle
Martin et al., 1990; Carbone et al., 1991; Chumakov et al.,
1991; McDaniel et al., 1991; Prosser & Condie, 1991), and
since a mutation does not necessarily alter protein function,
we sequenced the samples with shifted bands and analysed
protein expression by immunohistochemistry. Of the 15
samples sequenced, one nonsense mutation was observed and
we could not show a mutation in one other sample. These
two tumours were in fact not stained by the antibody to p53.
Mutations, except for one in exon 10, were found exclusively
in exons 5-8, which are regions highly conserved between
species and which contain the usual mutational hotspots, as
reported by others (Prosser et al., 1990; Davidoff et al.,
1991a; Osborne et al., 1991; Coles et al., 1992). In this series,
tumour mutations were scattered throughout the DNA-
spanning exons 5-8, and we did not find either specific
mutations or mutational hotspots as seen in tumours induced
by chemical carcinogens or UV irradiation. Eight out of 12
point mutations were G:C to A:T transitions, with one
G-*A transition occurring at one of the cpG dinucleotides
(codon 248) supposed to proceed from deamination of a
methylcytosine and known to be a hotspot for spontaneous
mutation (Hollstein et al., 1991; Jonveaux et al., 1991). The
four other cases were transversions. A high prevalence of
transitions favours spontaneous mutations (Caron de
Fromentel et al., 1991). However one C-*T transition occur-
red at a CC dimer, which is known to be provoked by UV
light damage (Moles et al., 1993).
One of the four transversions was a G-T substitution,
known in lung cancer to be caused by benzopyrenes con-
tained in tobacco smoke (Suzuki et al., 1992). One tumour
with a shifted band on exon 6 was unavailable for sequence,
and although improbable, in this case we cannot exclude a
silent polymorphism at codon 213 (Carbone et al., 1991)
since the tumour was positively stained with anti-p53
antibody. We cannot speculate ifevery mutation encountered
has the same prognostic value since each mutation alters the
p53 conformation differently, leading to different biological
properties and tumorigenic potential (Halevy et al., 1990;
Raycroft et al., 1991; Mukhopadhyay & Roth, 1993).
Mutants on exons 5 and 6 encode conformers which bind
heatshock proteins (hsp7o) and are associated with humoral
responses, whereas exons 7 and 8 do not (Callahan et al.,
1992; Davidoff et al., 1992a; Schlichtholz et al., 1992).
Owing to its extremely short half-life, normal p53 protein
is undetectable by IHC. Point mutations are believed to
change its conformation, resulting in prolongation of its
half-life (Hinds et al., 1989) and its detection by IHC. To
better correlate mutations with protein stability, immuno-
histochemical studies were performed. Of 16 tumours with a
band shift, 12 exhibited overexpression of p53. Of the four
samples with band shift associated with lack of immunoreac-
tivity, one had no detectable mutation, one had a nonsense
mutation, one a missense mutation and one an intronic
insertion. This last type of mutation may generate a shorter
and modified mRNA, leading to a truncated protein. The
first two examples raise the issue of technical problems linkedp53 IN LOCALLY ADVANCED BREAST CANCER 1149
to the heterogeneity of the tumours, suggesting that micro-
dissection and PCR in situ would be of greater specificity
than classical techniques. Only two tumours without- any
band shift were heavily stained with PAb 1801. Elledge et al.
(1993) found in breast tumours a lower prevalence of muta-
tions of p53 detected by SSCP than with immunohisto-
chemical staining. Other investigators have found either
mutations recognised at molecular level but negative by
immunohistochemistry (Rodrigues et al., 1990; Bennet et al.,
1991; Borresen et al., 1991) or overexpression of a stable
apparently wild-type protein. This was recently reported in
undifferentiated neuroblastoma cell lines (Davidoff et al.,
1992b) and in normal epithelial and mesenchymal cells in
certain forms of hereditary breast tumours (Barnes et al.,
1992). However, there is an abundance of reports of a good
correlation between protein detection and the presence of
mutation at gene level (Bartek et al., 1990; Borresen et al.,
1991; Davidoff et al., 1991a; Varley et al., 1991).
As in other reports, we found marked heterogeneity of
staining (Cattoretti et al., 1989; Davidoff et al., 1991a;
Thompson et al., 1992; Thor et al., 1992). Three types of
staining were observed in our tumours: large isolated foci of
tumour cells within a negative population of cancer cells;
dispersed positive cells; and mixed heterogeneous positive
cells. The localisation of staining was usually exclusively
nuclear. Two tumours had mixed nuclear/cytoplasmic stain-
ing and one had cytoplasmic staining only.
Cytoplasmic staining with nuclear sparing has been de-
scribed by Moll et al. (1992) in normal lactating breast
epithelial cells and in some breast cancers, in which case this
type of staining correlated with wild-type p53. This indicates
that inactivation of p53 may be obtained through mechan-
isms involving sequestration of p53 protein in the cyto-
plasm.
This work was conducted as a pilot study in an infrequent
group of patients in Western countries (McGuire et al.,
1991). All of them had LABC (stage III-IV), 31 (82%) had
an IBC (T4d) as diagnosed after surgical biopsy, and all
patients were treated with an identical intensive therapy
regimen.
Tumours with p53 mutations were significantly larger
(x2 = 7.490, P = 0.0062) and more often metastatic at the
time of diagnosis (x2 = 10.113; P = 0.0015). Six of eight
tumours with a diameter greater than 10 cm had a p53
mutation, and all were in patients with metastases. Five of
these six patients relapsed after an initial response to therapy,
three as a result of CNS disease. Less significantly, tumours
with p53 mutations were related to already known (Horak et
al., 1992; Poller et al., 1992) poor prognostic characteristics
such as absence of oestrogen receptors.
In conclusion, these clinicopathological correlations and
the initial response to treatment link p53 mutations with
poor prognosis and suggest that within this subset of patients
with a severe prognostic form of cancer p53 mutations are
related to the more aggressive forms.
A preferential association ofp53 mutations with the size of
the tumour, the heterogeneity of staining and the presence of
metastasis leads to the postulate that p53 mutagenesis could
give a selective growth advantage and could be a late event in
breast tumour evolution.
We wish to thank Thierry Soussi for fruitful discussions on the p53
gene and on the PCR-SSCP technique and for providing us with
some of the primers used, Carolyne Moyret for introduction to
sequence analysis of p53, Rima Zoorob for fruitful discussions and
introduction to TA cloning, and Charles Auffray and Dominique
Piattier for discussions.
References
BAKER, S.J., FEARON, E.R., NIGRO, J.M., HAMILTON, S.R., PRE-
ISINGER, A.C., JESSUP, J.M., VANTUINEN, P., LEDBETTER, D.H.,
BARKERS, D.F., NAKAMURA, Y., WHITE, R.L. & VOGELSTEIN,
B. (1989). Chromosome 17 deletions and p53 mutations in col-
orectal carcinomas. Science, 2A4, 217-221.
BAKER, S.J., REISINGER, A.C., JESSUP, J.M., PARASKEVA, C., MAR-
KOWITZ, S., WILSON, J.K., HAMILTON, S. & VOGELSTEIN, B.
(1990a). P53 gene mutations occur in combination with 17p
allelic deletion as late events in colorectal tumorigenesis. Cancer
Res., 50, 7717-7722.
BAKER, S.J., MARKOWITZ, S., FEARON, E.R., WILSON, J.K. &
VOGELSTEIN, B. (1990b). Suppression of human colorectal car-
cinoma cell growth by wild type p53. Science, 249, 912-915.
BANKS, L., MATLASHEWSKI, G. & CRAWFORD, L. (1986). Isolation
of human p53 specific monoclonal antibodies and their use in the
studies of human p53 expression. Eur. J. Biochem., 159,
529-534.
BARNES, D.M., HANBY, A.M., GILLETT, C.E., MOHAMMED, S.,
HODGSON, S., BEBROW, L.G., LEIGH, I.M., PURKIS, T.,
MACGEOCH, C., SPURR, N.K., BARTEK, J., VOJTESEK, B., PICK-
SLEY, S.M. & LANE, D.P. (1992). Abnormal expression of wild
type p53 protein in normal cells of a cancer family patient.
Lancet, 340, 259-263.
BARTEK, J., IGGO, R., GANNAN, J. & LANE, D.P. (1990). Genetic and
immunochemical analysis of mutant p53 in human breast cancer
cell lines. Oncogene, 5, 893-899.
BEAHRS, O.H., HENSON, D.E., HUTTER, R.V.P. & MYERS, M.H.
(1988). Manual for Staging of Cancer, 3rd edn, pp. 145-150.
Lippincott: Philadelphia.
BENNET, W.P., HOLLSTEIN, M.C., HE, A., ZHU, S.M., RESEAU, J.H.,
TRUMP, B.F., METCALF, R.A., WELSH, J.A., MIDGLEY, C., LANE,
D.P. & HARRIS, C.C. (1991). Archival analysis of p53 genetic and
protein alterations in Chinese oesophageal cancer. Oncogene, 6,
1779-1784.
BORRESEN, A.L., HOVIG, E., SMITH-SORENSEN, B., MALKIN, D.,
LYSTAD, S., ANDERSEN, T.I., NESLAND, J.M., ISSELBACHER,
K.J. & FRIEND, S.H. (1991). Constant denaturant gel electro-
phoresis as a rapid screening technique for p53 mutation. Proc.
Natl Acad. Sci. USA, 88, 8405-8409.
BUCHMAN, L., CHUMAKOV, P.M., NINKINA, N.N., SAMARINA, O.P.
& GEORGIEV, G.P. (1988). A variation in the structure of the
protein-coding region of the human p53 gene. Gene, 70,
245-252.
CALLAHAN, R. (1992). p53 mutations, another breast cancer prog-
nostic factor. Proc. Natl Acad. Sci. USA, 84, 826-827.
CARBONE, D., CHIBA, I. & MITSUDOMI, T. (1991). Polymorphism at
codon 213 within the p53 gene. Oncogene, 6, 1691-1692.
CARON DE FROMENTEL, C. & SOUSSI, T. (1991). TP 53 tumor
suppressor gene: a model for investigating human mutagenesis.
Genes. Chrom. Cancer, 4, 1-17.
CATTORETTI, G., RILKE, F., ANDREOLA, S., D'AMATO, L. & DELIA,
D. (1989). P53 expression in breast cancer. Int. J. Cancer, 41,
1780-1786.
CHUMAKOV, P.M. & JENKINS, J.R. (1991). BstNI/NciI polymor-
phism of the human p53 gene (TP53). Nucleic Acids Res., 19,
6969.
CLARKE, A.R., PURDIE, C.A., HARRISON, D.J., MORRIS, R.G., BIRD,
C.C., HOOPER, M.L. & WYLLIE, A.H. (1993). Thymocyte apop-
tosis induced by p53 dependent and independent pathways.
Nature, 362, 849-852.
COLES, C., CONDIE, A., CHUTTY, V., EVANS, H.J. & PROSSER, J.
(1992). P53 mutations in breast cancers. Cancer Res., 52,
5291-5299.
DAVIDOFF, A.M., HUMPHREY, P.A., IGLEHART, J.D. & MARKS, J.R.
(1991a). Genetic basis for p53 overexpression in human breast
cancer. Proc. Natl Acad. Sci. USA, 88, 5006-5010.
DAVIDOFF, A.M., KERNS, B.J.M., IGLEHART, J.D. & MARKS, J.R.
(1991b). Maintenance of p53 alterations throughout breast cancer
progression. Cancer Res., 51, 2605-2610.
DAVIDOFF, A.M., IGLEHART, J.D. & MARKS, J.R. (1992a). Immune
response to p53 is dependent upon p53/HSP70 complexes in
breast cancers. Proc. Natl Acad. Sci. USA, 88, 3439-3442.
DAVIDOFF, A.M., PENCE, J.C., SHORTER, N.A., IGLEHART, J.D. &
MARKS, J.R. (1992b). Expression of p53 in human neuroblastoma
and neuroepithelioma derived cell lines. Oncogene, 7, 127-133.
DE LA CALLE MARTIN, O., FABREGAT, V., ROMERO, M., SOLER, J.,
VIVES, J. & YAGUE, J. (1990). AccIl polymorphism of the p53
gene. Nucleic Acids Res., 18, 4963.1150 A. FAILLE et al.
DILLER, L., KASSEL, J., NELSON, C.E., GRYKAMA, E., LITWAK, G.,
GEBHARDT, M., BRESSAC, B., OZTURK, M., BAKER, S.J.,
VOGELSTEIN, B. & FRIEND, S.H. (1990). P53 functions as a cell
cycle control protein in osteosarcomas. Mol. Cell. Biol., 10,
5772-5781.
ELLEDGE, R.M., FUQUA, S.A.W., CLARK, G.M., PUJOL, P., ALLRED,
D.C. & McGUIRE, W.L. (1993). Prognostic significance of p53
gene alterations in node-negative breast cancer. Breast Cancer
Res. Treat., 26, 225-235.
HALEVY, O., MICHALOVITZ, D. & OREN, M. (1990). Different tumor
derived p53 mutants exhibit distinct biological activities. Nature,
250, 113-116.
HINDS, P., FINJAY, C. & LEVINE, A.J. (1989). Mutation is required to
activate the p53 gene for cooperation with the ras oncogene and
transformation. J. Virol., 63, 739-746.
HOLLSTEIN, M., SIDRANSKY, D., VOGELSTEIN, B. & HARRIS, C.C.
(1991). p53 mutations in human cancers. Science, 253, 49-53.
HORAK, E., SMITH, K., BROMLEY, L., LEJEUNE, S., GREENALL, M.,
LANE, D. & HARRIS, A.L. (1992). Mutant p53, EGF receptor and
c-erbB2 expression in human breast cancer. Oncogene, 6,
2277-2284.
JAIYESIMI, I.A., BUZDAR, A.V. & HORTOBAGUY, G. (1992).
Inflammatory breast cancer. A review. J. Clin. Oncol., 10,
1014-1024.
JONVEAUX, P., FENAUX, P., QUIQUANDON, I., PIGNON, J.M., LAI,
J.L., LOUCHEUX-LEFEBVRE, M.H., GOOSSENS, M., BAUTERS, F.
& BERGER, R. (1991). Mutations in the p53 gene in myelodys-
plastic syndromes. Oncogene, 6, 2243-2247.
LANE, D.P. (1992). p53, guardian of the genome. Nature, 358,
15-16.
LANE, D.P. (1993). A death in the life of p53. Nature, 362,
786-787.
LEVINE, P.H., STEINHORN, S.C., GLOECKLER, R.L. & ARON, J.L.
(1985). Inflammatory breast cancer: the experience of the surveil-
lance, epidemiology, and end results (SEER) program. J. Natl
Cancer Inst., 74, 291-297.
LEVINE, A.J., MOMAND, J. & FINLAY, C.A. (1991). The p53 tumour
suppressor gene. Nature, 351, 453-456.
LOWE, S.W., SCHMITT, E.M., SMITH, S.W. & OSBORNE, B.A. (1993).
P53 is required for radiation induced apoptosis in mouse
thymocytes. Nature, 362, 847-849.
MCDANIEL, T., CARBONE, D., TAKAHASHI, T., CHUMAKOV, P.,
CHANG, E.H., PIROLLO, K.F., YIN, J., HUANG, Y. & MELTZER, S.
(1991). The MspI polymorphism in intron 6 of p53 (TP53)
detected by digestion of PCR products. Nucleic Acids Res., 19,
4796.
McGUIRE, W.L. (1991). Breast cancer prognostic factors: evaluation
guidelines. J. Natl Cancer Inst., 83, 154-155.
MANIATIS, T., FRITSCH, E.F. & SAMBROOK, J. (1982). Nuclear Clon-
ing: A Laboratory Manual, pp. 282-285. Cold Spring Harbor
Laboratory Press: Cold Spring Harbor, NY.
MAZARS, R., SPINARDI, L., BEN-CHEIKH, M., SIMONY-
LAFONTAINE, J., JEANTEUR, P. & THEILLET, C. (1992). p53
mutations occur in aggressive breast cancer. Cancer Res., 52,
3918-3923.
MOLES, J.P., MOYRET, C., GUILLOT, B., JEANTEUR, P., GUILHOU,
J., THEILLET, C. & BASSET-SEQUIN, N. (1993). P53 gene muta-
tions in human epithelial skin cancers. Oncogene, 8, 583-588.
MOLL, U.M., RIOU, G. & LEVINE, A.J. (1992). Two distinct
mechanisms alter p53 in breast cancer: mutation and nuclear
exclusion. Proc. Natl Acad. Sci. USA, 89, 7262-7266.
MUKHOPADHYAY, T., & ROTH, J.A. (1993). A codon 248 p53 muta-
tion retains tumor suppressor function as shown by enhancement
of tumor growth by antisense p53. Cancer Res., 53,
4362-4366.
NIGRO, J.M., BAKER, S.J., PREISINGER, A.C., JESSUP, J.M., HOSTET-
TER, R., CLEARY, K., BIGNER, S.H., DAVIDSON, N., BAYLIN, S.,
DEVILEE, P., GLOVER, T., COLLINS, F.C., WESTON, A., MODALI,
R., HARRIS, C.C. & VOGELSTEIN, B. (1989). Mutations in the p53
gene occur in diverse tumor types. Nature, 342, 705-708.
ORITA, M., SUZUKI, Y., SEKIYA, T. & HAYASHI, K. (1989). A rapid
and sensitive detection of point mutations and genetic polymor-
phisms using polymerase chain reaction. Genomics, 5,
874-879.
OSBORNE, R.J., MERLO, G.R., MITSUDOMI, T., VENERIO, T., LISCIA,
D.S., CAPPA, P.M., CHIBA, I., TAKAHASHI, T., NAU, M.N., CAL-
LAHAN, R. & MINNA, J.D. (1991). Mutations in the p53 gene in
primary human breast cancers. Cancer Res., 51, 6194-6198.
POLLER, D.N., HUTCHINGS, C.E., GALEA, M., BELL, J.A., NICHOL-
SON, R.A., ELSTON, C.W., BLAMEY, R.W. & ELLIS, I.O. (1992).
P53 protein expression in human breast carcinoma: relationship
to expression of epidermal growth factor receptor, c-erbB-2 pro-
tein overexpression, and oestrogen receptor. Br. J. Cancer, 66,
583-588.
PROSSER, J. & CONDIE, A. (1991). Biallelic Apal polymorphism of
the human p53 gene (TP53). Nucleic Acids Res., 19, 4799.
PROSSER, J., THOMSON, A.M., CRANSTON, G. & EVANS, H.J. (1990).
Evidence that p53 behaves as a tumor suppressor gene in
sporadic breast tumors. Oncogene, 5, 1573-1579.
RAYCROFT, L., SCHNIDT, J.R., YOAS, K., HAO, M. & LOZANO, G.
(1991). Analysis of p53 mutants for transcriptional activity. Mol.
Cell. Biol., 11, 6067-6074.
RODRIGUES, N.R., ROWAN, A., SMITH, M.E.F., KERR, I.B.,
BODMER, W.F., GANNON, J.V. & LANE, D.P. (1990). p53 muta-
tions in colorectal cancer. Proc. Natl Acad. Sci. USA, 87,
7555-7559.
SCHLICHTHOLZ, B., LEGROS, Y., GILLET, D., GAILLARD, C.,
MARTY, M., LANE, D., CALVO, F. & SOUSSI, T. (1992). The
immune response to p53 in breast cancer patients is directed
against immunodominant epitopes unrelated to the mutational
hot spot. Cancer Res., 52, 6380-6384.
SHERRY, M.M., JOHNSON, D.H., PAGE, D.L., GRECO, F.A. & HAINS-
WORTH, J.D. (1985). Inflammatory carcinoma of the breast.
Clinical review and summary of the Vanderbilt experience with
multimodality therapy. Am. J. Med., 79, 355-364.
SPINARDI, L., MAZARS, R. & THEILLET, C. (1991). Protocols for an
improved detection of point mutations by SSCP. Nucleic Acids
Res., 19, 4009.
SUZUKI, H., TAKAHASHI, T., KUROISHI, T., SUYAMA, M.,
ARIYOSHI, Y., TAKAHASHI, T. & UEDA, R. (1992). P53 muta-
tions in non small cell lung cancer in Japan: association between
mutations and smoking. Cancer Res., 52, 734-736.
THOMPSON, A.M., ANDERSON, T.J., CONDIE, A., PROSSER, J.,
CHETTY, U., CARTER, D.C., EVANS, H.J. & STEEL, C.M. (1992).
P53 Allele losses, mutations and expression in breast cancer and
their relationship to clinicopathological parameters. Int. J.
Cancer, 50, 528-532.
THOR, A.D., MOORE, D.H., EDGERTON, S.M., KAWAZAKI, E.S.,
REIHSAUS, E., LYNCH, H.T., MARCUS, J.N., SCHWARTZ, L.,
CHEN, L.C., MAYALL, B.H. & SMITH, H.S. (1992). Accumulation
of p53 tumor suppressor gene protein: an independent marker of
prognosis in breast cancers. J. Natl Cancer Inst., 84,
845-855.
VARLEY, J.M., BRAMMAR, W.J., LANE, D.P., SWALLOW, J.E.,
DOLAN, C. & WALKRE, R.A. (1991). Loss of chromosome 17pl3
sequences and mutations of p53 in human breast carcinomas.
Oncogene, 6, 413-421.
WORLD HEALTH ORGANIZATION (1982). Histological typing of
breast tumors. Tumori, 68, 181-198.